Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Barbara Coffey, MD, MS, Chief, Tics and Tourette’s Clinical and Research Program, Icahn School of Medicine at Mount Sinai, will present a poster at the 62nd Annual Meeting of theAmerican Academy of Child and Adolescent Psychiatry being held at the Henry B. Gonzalez Convention Center in San Antonio, Texas from October 26-31. The poster, entitled, “Vigabatrin in Patients with Treatment-Resistant Tourette’s Disorder: A Proof-of-Concept Study”, (Poster # NRPOSTER-2.23) will be presented at the conference from 10:00 am to 12:30 pm CDT on October 29th. The poster will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
The poster presents preliminary data on safety and effectiveness obtained from a proof-of-concept, 8-week, open-label trial evaluating CPP-109 (vigabatrin) in patients with Treatment-Refractory Tourette’s Disorder conducted by Dr. Coffey, in collaboration with Dr. Jonathan D. Brodie at the NYU Langone Medical Center, the Co-Principal Investigator and lead inventor of this use of GABA-AT inhibitors. The trial was designed to evaluate the potential effect of GABA-aminotransferase inhibition by vigabatrin as a mechanism for reducing tics in subjects at least 18 years of age with a DSM-IV-TR diagnosis of Tourette’s Disorder, who exhibited unsatisfactory response to all prior treatments.
Vigabatrin was used as a “research surrogate” to demonstrate the utility of GABA-aminotransferase (GABA-AT) blockade, with the expectation that upon successfully demonstrating the utility of this mechanism, further development activities would focus on the potentially safer, more potent GABA-AT inhibitor, CPP-115. In addition, Catalyst is developing a generic equivalent of Sabril® (vigabatrin). (Original Source)
Shares of Catalyst Pharmaceutical closed yesterday at $3.34. CPRX has a 1-year high of $5.80 and a 1-year low of $2.55. The stock’s 50-day moving average is $3.54 and its 200-day moving average is $4.01.
On the ratings front, CPRX has been the subject of a number of recent research reports. In a report issued on September 10, Roth Capital analyst Scott Henry maintained a Buy rating on CPRX, with a price target of $7, which represents a potential upside of 109.6% from where the stock is currently trading. Separately, on August 11, Piper Jaffray’s Charles Duncan reiterated a Buy rating on the stock and has a price target of $7.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Scott Henry and Charles Duncan have a total average return of 13.8% and 7.2% respectively. Henry has a success rate of 43.4% and is ranked #217 out of 3802 analysts, while Duncan has a success rate of 43.1% and is ranked #817.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.